参考文献: [1].Partridge A, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13).2022 SABCS....
Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy. Fedro Peccatori, MD, PhD Breastfeeding has been demonstrated to be feasible for patients with hormone recept...
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 TrialCDK4/6 inhibitorsContinuous daily low-doseHER2-positiveRibociclibTrastuzumabPreclinical studies have demonstrated that cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors can resensitize HER2-positive ...
FULL PAPER British Journal of Cancer (2014) 110, 1139–1147 | doi: 10.1038/bjc.2013.831 Keywords: HER2-positive breast cancer; lapatinib; neoadjuvant; trastuzumab; biomarkers Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial E...
assigned (1:1) to receive either olaparib or placebo for one year following completion of chemotherapy, surgery, and radiation. Based on previous results from the trial, olaparib wasapprovedin 2022 in the adjuvant setting for certain patients with HER2-negative, BRCA-positive breast cancer. ...
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17, 367–377 (2016). Article CAS Google Scholar Chan, A. et al. Final efficacy results of ...
The results of the previous reported trial from the California Cancer Registry showed that the survival of ER/PgR positive/HER-2 positive subtype was superior to that of ER positive/PgR negative/HER-2 positive subtype across all stages, confirming the relevant role of PgR on survival even in ...
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42. Article PubMed PubMed...
3 Metastatic Breast Cancer Trial Source: Streetwise Reports (10/20/21) Shares of Radius Health Inc. traded 17% higher after the firm reported positive topline results from the Phase 3 EMERALD study of elacestrant in ER+/HER2- advanced or metastatic breast ...
19 Here we report initial results of a phase 3 randomized clinical trial of margetuximab vs trastuzumab, each combined with single-agent chemotherapy, in pretreated patients with ERBB2-positive ABC. In addition, we present an exploratory analysis of PFS and OS by FcγR genotype. Methods Study...